HIV drug resistance to integrase inhibitors in low- and middle-income countries

Joseph Fokam^{1

2

3

4}, Seth Inzaule⁵, Vittorio Colizzi⁶, Carlo-Federico Perno^{1

7}, Jean Kaseya⁸, Nicaise Ndembi^{9

10

11}

Affiliations

¹ Chantal BIYA International Reference Centre for research on HIV/AIDS prevention and management, Yaoundé, Cameroon.
² Faculty of Health Sciences, University of Buea, Buea, Cameroon.
³ National HIV Drug Resistance Group, Ministry of Public Health, Yaoundé, Cameroon.
⁴ Faculty of Medicine and Biomedical Sciences, University of Yaoundé-I, Yaoundé, Cameroon.
⁵ Amsterdam Institute for Global Health and Development, Amsterdam, The Netherlands.
⁶ UNESCO Board of Biotechnology, University of Rome Tor Vergata, Rome, Italy.
⁷ Bambino Gesù IRCCS Pediatric Hospital, Rome, Italy.
⁸ Africa Centres for Disease Control and Prevention, Addis Ababa, Ethiopia.
⁹ Africa Centres for Disease Control and Prevention, Addis Ababa, Ethiopia. nicaise.ndembi@ihv.umaryland.edu.
¹⁰ Institute of Human Virology, University of Maryland School of Medicine, Baltimore, MD, USA. nicaise.ndembi@ihv.umaryland.edu.
¹¹ Kanazawa University, Graduate School of Medical Sciences, Ishikawa, Japan. nicaise.ndembi@ihv.umaryland.edu.

PMID: 38263265
PMCID: PMC11586446
DOI: 10.1038/s41591-023-02763-0

HIV drug resistance to integrase inhibitors in low- and middle-income countries

Joseph Fokam et al. Nat Med. 2024 Mar.

. 2024 Mar;30(3):618-619.

doi: 10.1038/s41591-023-02763-0.

Authors

Joseph Fokam^{1

2

3

4}, Seth Inzaule⁵, Vittorio Colizzi⁶, Carlo-Federico Perno^{1

7}, Jean Kaseya⁸, Nicaise Ndembi^{9

10

11}

Affiliations

¹ Chantal BIYA International Reference Centre for research on HIV/AIDS prevention and management, Yaoundé, Cameroon.
² Faculty of Health Sciences, University of Buea, Buea, Cameroon.
³ National HIV Drug Resistance Group, Ministry of Public Health, Yaoundé, Cameroon.
⁴ Faculty of Medicine and Biomedical Sciences, University of Yaoundé-I, Yaoundé, Cameroon.
⁵ Amsterdam Institute for Global Health and Development, Amsterdam, The Netherlands.
⁶ UNESCO Board of Biotechnology, University of Rome Tor Vergata, Rome, Italy.
⁷ Bambino Gesù IRCCS Pediatric Hospital, Rome, Italy.
⁸ Africa Centres for Disease Control and Prevention, Addis Ababa, Ethiopia.
⁹ Africa Centres for Disease Control and Prevention, Addis Ababa, Ethiopia. nicaise.ndembi@ihv.umaryland.edu.
¹⁰ Institute of Human Virology, University of Maryland School of Medicine, Baltimore, MD, USA. nicaise.ndembi@ihv.umaryland.edu.
¹¹ Kanazawa University, Graduate School of Medical Sciences, Ishikawa, Japan. nicaise.ndembi@ihv.umaryland.edu.

PMID: 38263265
PMCID: PMC11586446
DOI: 10.1038/s41591-023-02763-0

No abstract available

PubMed Disclaimer

Cited by

Treatment of Advanced HIV in the Modern Era.
Garland JM, Mayan H, Kantor R. Garland JM, et al. Drugs. 2025 Jul;85(7):883-909. doi: 10.1007/s40265-025-02181-1. Epub 2025 May 12. Drugs. 2025. PMID: 40354016 Free PMC article. Review.
The cumulative prevalence of HIV-1 drug resistance in perinatal HIV.
Glenn JS, Bennett A, Mackie N, Lyall H, Fidler S, Taylor G, Foster C. Glenn JS, et al. AIDS. 2025 Jul 15;39(9):1161-1177. doi: 10.1097/QAD.0000000000004202. Epub 2025 Apr 15. AIDS. 2025. PMID: 40235031 Free PMC article.
Brief communication: virological outcomes and dolutegravir resistance mutations in HIV-infected patients: a multicenter retrospective cohort study in Mozambique.
Doro Altan AM, Majid N, Orlando S, Uamusse E, Rafael M, Sidumo Z, Guidotti G, Ciccacci F. Doro Altan AM, et al. AIDS Res Ther. 2025 Jan 30;22(1):8. doi: 10.1186/s12981-025-00708-w. AIDS Res Ther. 2025. PMID: 39885593 Free PMC article.
Do we need routine integrase resistance testing before starting antiretroviral therapy?
Kantor R, Pau AK, Kozal MJ, Hyle EP. Kantor R, et al. Lancet HIV. 2025 Jun 17:S2352-3018(25)00108-0. doi: 10.1016/S2352-3018(25)00108-0. Online ahead of print. Lancet HIV. 2025. PMID: 40541216 Free PMC article. Review.
Dolutegravir/Lamivudine Efficacy and Safety Outcomes in People With HIV-1 With or Without Historical Resistance Results at Screening: 48-Week Pooled Analysis.
Scholten S, Cahn P, Portilla J, Bisshop F, Hodder S, Ruane P, Kaplan R, Wynne BR, Man CY, Grove R, Wang R, Jones B, Ait-Khaled M, Kisare M, Okoli C. Scholten S, et al. Open Forum Infect Dis. 2024 Jul 1;11(7):ofae365. doi: 10.1093/ofid/ofae365. eCollection 2024 Jul. Open Forum Infect Dis. 2024. PMID: 39015350 Free PMC article. Clinical Trial.

References

1. The NAMSAL ANRS 12313 Study Group. N. Engl. J. Med 381, 816–826 (2019). - PubMed
1. Shafer R. In 30th International Workshop on HIV Drug Resistance and Treatment Strategies https://go.nature.com/47BYRUZ (2023).
1. Tao K. et al. Viruses 15, 1932 (2023). - PubMed
1. Xiao MA et al. Antimicrob. Agents Chemother 67, e0138622 (2023). - PMC - PubMed
1. Brenner BG et al. J. Antimicrob. Chemother 71, 1948–1953 (2016). - PMC - PubMed

Publication types

Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

HIV drug resistance to integrase inhibitors in low- and middle-income countries

Affiliations

HIV drug resistance to integrase inhibitors in low- and middle-income countries

Authors

Affiliations

Similar articles

Cited by

References

Publication types

MeSH terms

Substances

Grants and funding

LinkOut - more resources

Full Text Sources

Medical